Literature DB >> 6812032

Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.

W D Heston, D Kadmon, D W Lazan, W R Fair.   

Abstract

The R3327MAT-Lu tumor is a rapidly growing anaplastic derivative of the Dunning R3327 prostatic adenocarcinoma. We have found the ornithine decarboxylase (ODC) activity of this tumor to be as sensitive to inhibition by alpha-difluoromethylornithine (DFMO) as normal rat prostate. The same was true for all the other R3327 tumor derivatives we studied. The in vivo inhibition of ODC by DFMO allowed increased uptake of exogenously administered putrescine by the R3327AT tumor. Further, DFMO was inhibitory to the growth of the R3327MAT-Lu both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812032     DOI: 10.1002/pros.2990030408

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

Authors:  H I Scher; C Sternberg; W D Heston; R C Watson; D Niedzwiecki; T Smart; P Hollander; A Yagoda
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Authors:  Anne R Simoneau; Eugene W Gerner; Ray Nagle; Argyrios Ziogas; Sharon Fujikawa-Brooks; Hagit Yerushalmi; Thomas E Ahlering; Ronald Lieberman; Christine E McLaren; Hoda Anton-Culver; Frank L Meyskens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

Review 3.  The Emerging Clinical Role of Spermine in Prostate Cancer.

Authors:  Qiang Peng; Christine Yim-Ping Wong; Isabella Wai-Yin Cheuk; Jeremy Yuen-Chun Teoh; Peter Ka-Fung Chiu; Chi-Fai Ng
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.